ADC Therapeutics SA
ADCT
$3.70
-$0.26-6.57%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 40.37% | -12.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 40.37% | -12.80% | |||
| Cost of Revenue | -37.16% | -9.45% | |||
| Gross Profit | 147.15% | 4.21% | |||
| SG&A Expenses | 12.77% | 0.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.97% | -5.76% | |||
| Operating Income | 47.75% | 1.49% | |||
| Income Before Tax | 83.37% | 26.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 84.36% | 27.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.36% | 27.68% | |||
| EBIT | 47.75% | 1.49% | |||
| EBITDA | 47.75% | 0.34% | |||
| EPS Basic | 85.81% | 39.72% | |||
| Normalized Basic EPS | 89.08% | 20.01% | |||
| EPS Diluted | 85.81% | 39.72% | |||
| Normalized Diluted EPS | 89.08% | 20.01% | |||
| Average Basic Shares Outstanding | 10.15% | 19.96% | |||
| Average Diluted Shares Outstanding | 10.15% | 19.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||